KZA 10.5% 38.5¢ kazia therapeutics limited

Novogen - More Progress

  1. 3,567 Posts.

    ASX Code: NRT
    Announcement: Marshall Edwards & NIDCR join forces to study Phenoxodiol

    Date: 24 July 2002 - 14:37:55
    Market Sensitive: No

    NOVOGEN LIMITED 2002-07-24 ASX-SIGNAL-G

    HOMEX - Sydney

    +++++++++++++++++++++++++
    MEDIA RELEASE

    Novogen's listed subsidiary, Marshall Edwards Inc (AIM:MSH), has
    signed a Materials Cooperative Research and Development Agreement
    with the National Institute of Dental and Craniofacial Research
    (NIDCR), an Agency of the National Institutes of Health in the USA.

    The NIDCR is actively involved in research on novel therapies to
    treat oral, as well as head and neck, cancers. The agreement with the
    NIDCR is part of an international collaboration to further define the
    clinical applications of phenoxodiol.

    Phenoxodiol is under development as a primary anti-cancer therapy for
    a broad range of human cancers and is currently being tested in
    clinical trials in patients with advanced cancers in American and
    Australian hospitals.

    Phenoxodiol is the first anti-cancer drug licensed by Marshall
    Edwards Inc from Novogen Limited. This drug stems from the research
    program established by Novogen that has identified a family of
    compounds with novel anti-cancer actions. Marshall Edwards Inc has
    an option on all other Novogen anti-cancer compounds.

    Dr Graham Kelly, Chairman of Marshall Edwards Inc said "In addition
    to phenoxodiol, Novogen has identified a number of similar compounds
    that are showing selective activity against a number of common human
    cancers.

    "The action of these drugs against targets so fundamental to cancer
    cell survival suggests that they can kill cancer cells independent of
    the type of mutation behind the cancer and independent of their
    development of resistance to other drugs."

    Marshall Edwards Inc (AIM:MSH) was listed on the London Stock
    Exchange's Alternative Investment Market in May 2002.

    For further information:

    Professor Alan Husband
    RESEARCH DIRECTOR

    Dr Graham Kelly
    PHENOXODIOL PROGRAM DIRECTOR
    Novogen Limited

    TEL (02) 9878 0088
    http://www.novogen.com


 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Last
38.5¢
Change
-0.05(10.5%)
Mkt cap $18.63M
Open High Low Value Volume
38.5¢ 38.5¢ 38.5¢ $2.938K 7.631K

Buyers (Bids)

No. Vol. Price($)
3 15841 38.5¢
 

Sellers (Offers)

Price($) Vol. No.
39.5¢ 1500 1
Last update - 10.04am 19/10/2018 (20 minute delay) ?
KZA (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.